SGLT-2 Inhibitors Tied to Lower Risk for Autoimmune Rheumatic Diseases in Adults With T2D
Among adults with type 2 diabetes, SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases compared with sulfonylureas.
A study published online found that Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes.
Researchers from Sungkyunkwan University in the Republic of Korea, led by Bin Hong, examined use of SGLT-2 inhibitors and the risk for autoimmune rheumatic diseases in a retrospective cohort study involving 2,032,157 adults with type 2 diabetes.
- The study included 1,030,088 SGLT-2 inhibitor initiators and 1,002,069 sulfonylurea initiators after propensity score weighting.
- The weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.
No direct quote available in the text.
Author's summary: SGLT-2 inhibitors reduce autoimmune disease risk.